BRIEF—IQVIA Oncology trends report 2023

25 May 2023

According to the latest report from IQVIA Institute for Human Data Science, global oncology R&D activity remains high and more patients have been treated for cancer.

A link to the full report is provided below, but among its key findings are:

Spending on cancer medicines is expected to reach $375 billion globally by 2027, up from $196 billion in 2022;
For approved medicines, the number of patients treated globally has increased annually by an average of 5% over the past five years
Oncology trial starts remained at historically high levels in 2022, up 22% from 2018;
Emerging biopharma companies led innovation in oncology in 2022 and account for 71% of the pipeline; and
Oncology clinical trial representation for Black/African American and Hispanic patients was well below the reported 2019 US cancer incidence rate.

https://www.businesswire.com/news/home/20230524005132/en/Global-Oncology-RD-Activity-Remains-High-and-More-Patients-Have-Been-Treated-for-Cancer-says-IQVIA-Institute-for-Human-Data-Science